NEW YORK, Sept. 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Endo International plc (NASDAQ:ENDP) between November 30, 2012 and July 6, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Bier v. Endo International plc, et al. (Case No. 2:17-cv-03711-TJS) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/endo-international-plc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana ER. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
If you suffered a loss in Endo you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
First Western Ship Transits Strait of Hormuz Since Iran War Began 



